NCT06501989 2026-02-11
Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer
Inova Health Care Services
Phase 2 Withdrawn
Clinical Trials
32 trialsNCT03563144 2025-02-21
QUILT-3.088: NANT Pancreatic Cancer Vaccine
ImmunityBio, Inc.
Phase 2 Withdrawn
NCT04863430 2025-02-21
Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the Stomach
Peking University
Phase 2 Withdrawn
NCT03722498 2023-07-11
Phase â…¡ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE
Sun Yat-sen University
Phase 2 Withdrawn
NCT04796454 2022-06-01
PAMICC
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Withdrawn
NCT04418895 2021-11-10
Neoadjuvant Therapy for Localized Rectal Adenocarcinoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Withdrawn
NCT04430985 2021-10-27
IMMUNOX
Herlev Hospital
Phase 2 Withdrawn
NCT02129322 2021-02-15
Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1
Zhejiang University
Phase 2 Withdrawn
NCT04145193 2020-09-21
Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC
MedImmune LLC
Phase 2 Withdrawn
NCT00728000 2019-11-25
Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic Adenocarcinoma
University of Cincinnati
Phase 2 Withdrawn
NCT01524575 2019-09-25
Gemcitabine and Oxaliplatin in the Management of Metastatic Pancreatic Cancers With Low Expression of ERCC1
University of Hawaii
Phase 2 Withdrawn
NCT03161574 2019-08-08
FOLFOXIRI Chemotherapy Alone as Neoadjuvant Treatment for Circumferential Radial Margin (CRM) Positive Rectal Cancer
Guangxi Medical University
Phase 2 Withdrawn
NCT03161041 2018-11-14
Perioperative Chemotherapy With Bevacizumab for Colorectal Carcinomatosis French Part of the Main Bev-IP Study
Hospices Civils de Lyon
Phase 2 Withdrawn
NCT03222089 2018-03-27
Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC
Fujian Cancer Hospital
Phase 2 Withdrawn
NCT02345746 2017-08-24
Hepatic Arterial Infusion With FOLFOX Alone or in Combination With IV Chemotherapy in Colon Cancer With Liver Metastasis
Western Regional Medical Center
Phase 2 Withdrawn
NCT02079220 2017-07-31
A Phase II Study of Ziv-aflibercept in Combination With Capecitabine/Oxaliplatin (XELOX) Chemotherapy in the Front-Line Treatment of Patients With Metastatic Colorectal Cancer
University of Pittsburgh
Phase 2 Withdrawn
NCT00408772 2017-06-09
Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Patients With Colorectal Cancer
University of California, Davis
Phase 2 Withdrawn
NCT02856867 2017-05-09
MEGAN
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Withdrawn
NCT02413853 2017-04-17
PRIMIER
University of Southern California
Phase 2 Withdrawn
NCT01270438 2017-04-04
Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT02046538 2017-01-25
Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer
Weill Medical College of Cornell University
Phase 2 Withdrawn
NCT00571740 2016-07-06
Cetuximab and Bevacizumab as First-Line Therapy Followed By Combination Chemotherapy and Bevacizumab With or Without Cetuximab as Second-Line Therapy in Treating Patients With Stage IV Colorectal Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Withdrawn
NCT02296671 2016-03-08
Personalized Therapy for Esophagogastric Cancer Using Thymidylate Synthase Genetic Markers
Washington University School of Medicine
Phase 2 Withdrawn
NCT01889680 2014-12-02
Safety and Effectiveness Study of Chemotherapy and Ziv-aflibercept to Treat Metastatic Colorectal Cancer
NSABP Foundation Inc
Phase 2 Withdrawn
NCT01070290 2014-01-07
A Study of ARQ 197 Versus Investigator's Choice of Second-Line Chemotherapy in Patients With Locally Advanced or Metastatic Gastric Cancer Who Have Progressive Neoplastic Disease Following Treatment With One Prior Chemotherapy Regimen
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 2 Withdrawn
NCT01293942 2013-06-05
IXO+A in mCRC With Liver-only Metastases
Ottawa Hospital Research Institute
Phase 2 Withdrawn
NCT00118105 2013-01-03
S0408: Capecitabine, Oxaliplatin, and Bevacizumab in Pts Undergoing Surgery for Liver Mets From Colorectal Cancer
SWOG Cancer Research Network
Phase 2 Withdrawn
NCT00713687 2012-08-10
GemOx-PDT
Technical University of Munich
Phase 2 Withdrawn
NCT00070434 2012-06-07
S0304 Induct Chemo Then Chemo-RT in Pts w/Locally Advanced Adenocarcinoma of the Rectum
SWOG Cancer Research Network
Phase 2 Withdrawn
NCT01175291 2011-12-05
FOLFOX/Bevacizumab +/- MK-0646 in Metastatic Colorectal Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Withdrawn
NCT00988897 2009-12-23
Colorectal Cancer RECHALLENGE
Sanofi
Phase 2 Withdrawn
NCT00346099 2008-01-07
Study of Panitumumab Given First With Capecitabine and Oxaliplatin (CAPOX) and Then With Capecitabine and Radiation of the Pelvis for Treatment of Patients With Rectal Cancers That May or May Not Have Spread Beyond the Rectum
NSABP Foundation Inc
Phase 2 Withdrawn